BMS453

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 524479

CAS#: 166977-43-1

Description: BMS453 is a retinoic acid receptor β (RARβ) agonist in vivo and also RARα and RARγ antagonist in vitro. BMS453 inhibits breast cell proliferation by inducing active transforming growth factor β (TGFβ) and causes G1 arrest.


Chemical Structure

img
BMS453
CAS# 166977-43-1

Theoretical Analysis

MedKoo Cat#: 524479
Name: BMS453
CAS#: 166977-43-1
Chemical Formula: C27H24O2
Exact Mass: 380.18
Molecular Weight: 380.480
Elemental Analysis: C, 85.23; H, 6.36; O, 8.41

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: BMS453; BMS 453; BMS-453; BMS 189453; BMS-189453; BMS189453.

IUPAC/Chemical Name: Benzoic acid, 4-(2-(5,6-dihydro-5,5-dimethyl-8-phenyl-2-naphthalenyl)ethenyl)-, (E)-

InChi Key: VUODRPPTYLBGFM-CMDGGOBGSA-N

InChi Code: InChI=1S/C27H24O2/c1-27(2)17-16-23(21-6-4-3-5-7-21)24-18-20(12-15-25(24)27)9-8-19-10-13-22(14-11-19)26(28)29/h3-16,18H,17H2,1-2H3,(H,28,29)/b9-8+

SMILES Code: O=C(O)C1=CC=C(/C=C/C2=CC=C3C(C)(C)CC=C(C4=CC=CC=C4)C3=C2)C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 380.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Flamini MI, Gauna GV, Sottile ML, Nadin BS, Sanchez AM, Vargas-Roig LM. Retinoic acid reduces migration of human breast cancer cells: role of retinoic acid receptor beta. J Cell Mol Med. 2014 Jun;18(6):1113-23. doi: 10.1111/jcmm.12256. Epub 2014 Apr 10. PubMed PMID: 24720764; PubMed Central PMCID: PMC4508151.

2: Ali-Khan SE, Hales BF. Retinoid receptor antagonists alter the pattern of apoptosis in organogenesis stage mouse limbs. Toxicol Sci. 2006 Mar;90(1):208-20. Epub 2005 Dec 1. PubMed PMID: 16322074.

3: Lou YR, Miettinen S, Kagechika H, Gronemeyer H, Tuohimaa P. Retinoic acid via RARalpha inhibits the expression of 24-hydroxylase in human prostate stromal cells. Biochem Biophys Res Commun. 2005 Dec 30;338(4):1973-81. Epub 2005 Nov 7. PubMed PMID: 16289102.

4: Vine AL, Bertram JS. Upregulation of connexin 43 by retinoids but not by non-provitamin A carotenoids requires RARs. Nutr Cancer. 2005;52(1):105-13. PubMed PMID: 16091010.

5: Matt N, Ghyselinck NB, Wendling O, Chambon P, Mark M. Retinoic acid-induced developmental defects are mediated by RARbeta/RXR heterodimers in the pharyngeal endoderm. Development. 2003 May;130(10):2083-93. PubMed PMID: 12668623.

6: Chen R, Chen F, Han J, Miu J, Shao N, Oyang R. [Effects of selective RAR or/and RXR retinoids on the proliferation and differentiation of NB4 cells and their mechanisms]. Zhonghua Xue Ye Xue Za Zhi. 2001 May;22(5):256-9. Chinese. PubMed PMID: 11877083.

7: Yang L, Ostrowski J, Reczek P, Brown P. The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest. Oncogene. 2001 Nov 29;20(55):8025-35. PubMed PMID: 11753686.

8: Yang L, Munoz-Medellin D, Kim HT, Ostrowski J, Reczek P, Brown PH. Retinoic acid receptor antagonist BMS453 inhibits the growth of normal and malignant breast cells without activating RAR-dependent gene expression. Breast Cancer Res Treat. 1999 Aug;56(3):277-91. PubMed PMID: 10573118.

9: Blanchet S, Favier B, Chevalier G, Kastner P, Michaille JJ, Chambon P, Dhouailly D. Both retinoic acid receptors alpha (RARalpha) and gamma (RARgamma) are able to initiate mouse upper-lip skin glandular metaplasia. J Invest Dermatol. 1998 Aug;111(2):206-12. PubMed PMID: 9699718.